Given that CGRP, TRPV1, and SP are strongly implicated in driving neuroinflammation and neuropathic pain, both of which can accelerate tumor progression and bone destruction in metastases, their suppression implies a dual benefit of LipoNCs@pGSDMB: alleviating cancer-associated pain and disrupting the neuroinflammatory niche that fosters metastatic progression. Here, TRPV1 is linked to neoplasm.